AADR has submitted comments in response to the Food and Drug Administration’s (FDA) request for public comment on additional steps the FDA can take to reverse the opioid abuse epidemic. AADR’s comments strongly emphasized the need for both prescriber and patient training.
The FDA Opioid Policy Steering Committee (OPSC) was established in May 2017 and tasked with developing strategies for fighting the opioid abuse epidemic. The OPSC’s four focus areas are 1) decreasing exposure to opioids and preventing addiction; 2) supporting opioid use disorder treatment; 3) promoting the development of new, less addictive pain therapies and 4) improving enforcement and revisiting the benefit/risk assessment of opioid therapies.
The request for comment was a follow-up to the National Academy of Medicine (NAM) report, “Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use”. AADR member Dr. Eli Eliav, an orofacial pain researcher at the University of Rochester, was a member of the NAM committee.
In comments to the OPSC, AADR stressed the importance of controlling the opioid abuse epidemic while allowing access to opioids for patients who really need them for pain control. AADR supported the NAM committee recommendations for more research to better understand pain and opioid use disorders, the opioid epidemic and public health considerations to inform the regulatory process. AADR supported the recommendation by the American Dental Association that nonsteroidal anti-inflammatory drugs should be the first-line pain medication for acute dental pain and advocated for the implementation of a national, mandatory prescription drug monitoring program. AADR also recommended mandatory provider training on how to prescribe opioids, recognize possible abuse and treat chemically-dependent patients.
For AADR’s full letter to the OPSC, please click here.